Cargando…

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States

RATIONALE AND OBJECTIVE: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval. This real-world database study examined outcomes for adult patients switching...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan, Al-Dakkak, Imad, Garlo, Katherine, Ong, Moh-Lim, Tomazos, Ioannis, Mahajerin, Arash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319830/ https://www.ncbi.nlm.nih.gov/pubmed/37415624 http://dx.doi.org/10.1016/j.xkme.2023.100683

Ejemplares similares

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
por: Mauch, Teri J, et al.
Publicado: (2023)

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data
por: Tomazos, Ioannis, et al.
Publicado: (2022)

Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review
por: Shahid, Kamran, et al.
Publicado: (2023)

Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation
por: Garlo, Katherine, et al.
Publicado: (2015)

Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry
por: Rondeau, Eric, et al.
Publicado: (2019)

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
por: Tanaka, Kazuki, et al.
Publicado: (2020)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016)

Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)

Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)

Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021)

The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022)

First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient
por: Jehn, Ulrich, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
por: Barbour, Thomas, et al.
Publicado: (2021)

Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab
por: Ehren, Rasmus, et al.
Publicado: (2021)

Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
por: Schmidt, Tilman, et al.
Publicado: (2022)

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017)

Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
por: Azad, Farhan, et al.
Publicado: (2023)

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
por: Jalbert, Arielle, et al.
Publicado: (2023)

A Case of Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
por: Thajudeen, B., et al.
Publicado: (2013)

Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab
por: Webb, Tennille N., et al.
Publicado: (2015)

Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab
por: Raufi, Alexander G., et al.
Publicado: (2016)

Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Atypical Hemolytic Uremic Syndrome After Liver Transplant Treated With Eculizumab
por: Bhatti, Sundus, et al.
Publicado: (2020)

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2018)

189 Eculizumab Therapy for Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Publicado: (2021)

Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
por: Ranabothu, Saritha, et al.
Publicado: (2021)

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J., et al.
Publicado: (2022)

Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J, et al.
Publicado: (2023)

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
por: Dorresteijn, Eiske M., et al.
Publicado: (2012)

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome
por: Vilalta, Ramon, et al.
Publicado: (2012)

Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
por: Tsai, Han-Mou, et al.
Publicado: (2014)

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab
por: Andries, Gabriela, et al.
Publicado: (2017)

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2019)

COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy
por: Gill, Jasmeet, et al.
Publicado: (2021)

The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center
por: Thomas, Katharine, et al.
Publicado: (2023)

Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?
por: Kakajiwala, Aadil, et al.
Publicado: (2016)

A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome
por: Quiroga, Borja, et al.
Publicado: (2016)

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome
por: Siedlecki, Andrew M., et al.
Publicado: (2018)

Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab
por: Tsai, Hsin Hsiang Clarence, et al.
Publicado: (2021)

Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
por: Busutti, Marco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u5qibev4jo2t0v7k3m39chce8h